Appendix C, attached herewith.

## REMARKS

Upon entry of the above amendment, claims 1-5, 7 and 10-11 will be pending in the captioned application. The amendments to the claims do not add any new matter within the meaning of 35 U.S.C. §132. Accordingly, the Examiner is respectfully requested to enter the above amendment before examination. If the Examiner has any questions regarding this submission, she is invited to telephone the undersigned attorney.

Respectfully submitted, NATH & ASSOCIATES PLLC

Bv:

Gary M. Nath

Registration No. 26,965

Sheldon M. McGee

Registration No. 50,454

Customer No. 34375

Date: March <u>ZY</u>, 2006 **NATH & ASSOCIATES PLLC** 112 South West Street Alexandria, VA 22314 (703)-548-6284 GMN/SMM\PA.doc

## Appendix AP20 Rec'd PCT/PTO 24 MAR 2006

## Claim Amendments

1. (Currently amended) Compounds A compound of formula I

in which

R1 is hydrogen or 1-4C-alkyl,

is hydrogen, halogen, hydroxyl, nitro, amino, R2 trifluoromethyl, 3-7C-cycloalkyl, alkyl, 3-7Ccycloalkyl-1-4C-alkyl, 1-4C-alkoxy, completely or predominantly fluorine-substituted 1-4C-alkoxy, 1-4Calkoxy-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkoxy, alkoxycarbonyl, mono- or di-1-4C-alkylaminocarbonyl, monodi-1-4C-alkylaminosulfonyl, or 1-4Calkylcarbonylamino, 1-4C-alkylsulfonylamino, phenyl, R21- and/or R211-substituted phenyl, phenyl-1-4C-alkyl, phenyl-1-4C-alkyl wherein the phenyl moiety substituted by R22, phenyl-1-4C-alkoxy, pyridyl, pyridyl substituted by R23, pyridyl-1-4C-alkyl, or pyridyl-1-4C-

alkyl wherein the pyridyl moiety is substituted by R24, in which

- is cyano, halogen, carboxyl, 1-4C-alkyl, 1-4C-alkoxy, aminocarbonyl, mono- or di-1-4C-alkylaminocarbonyl, 1-4C-alkylcarbonylamino, 1-4C-alkoxycarbonyl, aminosulfonyl, mono- or di-1-4C-alkylaminosulfonyl, amino, mono- or di-1-4C-alkylamino, trifluoromethyl, hydroxyl, phenylsulfonylamino or phenyl-1-4C-alkoxy,
- R211 is halogen or 1-4C-alkoxy,
- R22 is halogen, 1-4C-alkyl or 1-4C-alkoxy,
- R23 is halogen, 1-4C-alkyl or 1-4C-alkoxy,
- R24 is halogen, 1-4C-alkyl or 1-4C-alkoxy,
- R3 is hydrogen, halogen, 1-4C-alkyl or 1-4C-alkoxy,
- R4 is 1-4C-alkyl,
- R11 is 1-4C-alkyl,

and the salts, the N-oxides and the salts of the N-oxides of these compounds or a salt, N-oxide or a salt of an N-oxide thereof.

- 2. (Currently amended) Compounds The compound according to claim 1 in which
- R1 is hydrogen or 1-4C-alkyl,

```
R2 is hydrogen,
```

R3 is hydrogen,

R4 is methyl,

R11 is 1-4C-alkyl,

and the salts, the N-oxides and the salts of the N-oxides of these compounds or a salt, N-oxide or a salt of an N-oxide thereof.

3. (Currently amended)  $\frac{\text{Compounds}}{\text{Compound}}$   $\frac{\text{The compound}}{\text{claim 1 in which}}$ 

either

R1 is hydrogen,

R2 is hydrogen,

R3 is hydrogen,

R4 is methyl, and

R11 is methyl or ethyl,

or

R1 is methyl,

R2 is hydrogen,

R3 is hydrogen,

R4 is methyl, and

R11 is methyl,

and the salts, the N-oxides and the salts of the N-oxides of these compounds or a salt, N-oxide or a salt of an N-oxide thereof.

- 4. (Currently amended) Compounds The compound of formula I according to claim 1 in which R4 is methyl, and the salts, the N-oxides and the salts of the N-oxides of these compounds or a salt, N-oxide or a salt of an N-oxide thereof.
- 5. (Currently amended) Compounds The compound of formula I according to claim 1 in which R1 is hydrogen, R4 is methyl and R11 is methyl, and the salts, the N-oxides and the salts of the N-oxides of these compounds or a salt, N-oxide or a salt of an N-oxide thereof.
- 6. (Canceled)
- 7. (Currently amended) Pharmaceutical compositions A pharmaceutical composition containing one or more compounds of formula I according to claim 1, or a pharmaceutically acceptable salt, N-oxide or a salt of an N-oxide thereof, together with the usual pharmaceutical auxiliaries and/or

excipients a pharmaceutically suitable auxiliary and/or excipient.

## 8. - 9. (Canceled)

- 10. (Currently amended) A method for treating illnesses a chronic inflammatory disease of peripheral organs and the central nervous system (CNS) in a patient comprising administering to said patient a therapeutically effective amount of a compound of formula I according to claim 1, or a pharmaceutically acceptable salt, N-oxide or a salt of an N-oxide thereof.
- 11. (Currently amended) A method for treating <u>an</u> acute inflammatory <u>diseases</u> <u>disease</u> in a patient comprising administering to said patient a therapeutically effective amount of a compound of formula I according to claim 1, or a pharmaceutically acceptable salt, N-oxide or a salt of an N-oxide thereof.